Track topics on Twitter Track topics that are important to you
Type 2 diabetes is the leading cause of morbidity and mortality in the world. In Mexico it is the first cause of mortality, disability, and potential years of life lost due to premature death. The Mexican Institute of Social Security (IMSS) implemented the PREVENIMSS strategy. The aim of the current study was to estimate the program's effect on the mortality trend from type 2 diabetes, based on an interrupted time series analysis. At the beginning of the target period, the diabetes mortality rate was higher in IMSS beneficiaries than in the control population. After the program's implementation, there was a slight reduction in the mortality trend, while the control group showed an upward trend. Differences in the trends between the two groups suggest that they are not the exclusive result of institutional interventions. Living and work conditions could explain these differences.
This article was published in the following journal.
Name: Cadernos de saude publica
To investigate the characteristics of participants in the Diabetes Conversation Map™ (Map™) program who had higher vs. lower compliance to the program, to determine if program tailoring and monito...
Pre-diabetes is the underlying pathology for type 2 diabetes. The Diabetes Prevention Program is a proven, effective strategy to control or prevent type 2 diabetes; however, there is limited data on w...
To compare type 2 diabetes (T2D) patients included in a Diabetes Integrated Management (DIM) program with those followed in Diabetes Specialized Care (DSC), investigating differences in general charac...
The major efficacy trials on diabetes prevention have used resource-intensive approaches to identify high-risk individuals and deliver lifestyle interventions. Such strategies are not feasible for wid...
Our aim was to assess causes of death and temporal changes in excess mortality among patients with new-onset type 2 diabetes in Skaraborg, Sweden.
Translational study based on the American Association of Diabetes Educators 7 behaviors to manage Type 2 diabetes
A clinical study evaluating a three month digitally delivered lifestyle change program in adults with Type 2 Diabetes. The FareWell Program (the "Program") aims to reduce well-established ...
The primary purpose of this research is to demonstrate the therapeutic effects on diabetes, pre-diabetes and metabolic syndrome of implementing a well-formulated low carbohydrate lifestyle...
Type 2 diabetes is a chronic disease that affects approximately 13% of Portuguese population and is associated with a high cardiovascular mortality by coronary artery disease and cerebrova...
This is a study to examine if it is possible to fit a diabetes education program into the workflow of hospital nursing units for delivery at the bedside to individual diabetes patients and...
The time period before the development of symptomatic diabetes. For example, certain risk factors can be observed in subjects who subsequently develop INSULIN RESISTANCE as in type 2 diabetes (DIABETES MELLITUS, TYPE 2).
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
Component of the NATIONAL INSTITUTES OF HEALTH. It conducts and supports basic and applied research for a national program in diabetes, endocrinology, and metabolic diseases; digestive diseases and nutrition; and kidney, urologic, and hematologic diseases. It was established in 1948.
A severe type of hyperlipidemia, sometimes familial, that it is characterized by the elevation of both plasma CHYLOMICRONS and TRIGLYCERIDES contained in VERY-LOW-DENSITY LIPOPROTEINS. Type V hyperlipoproteinemia is often associated with DIABETES MELLITUS and is not caused by reduced LIPOPROTEIN LIPASE activity as in HYPERLIPOPROTEINEMIA TYPE I .
A cancer registry mandated under the National Cancer Act of 1971 to operate and maintain a population-based cancer reporting system, reporting periodically estimates of cancer incidence and mortality in the United States. The Surveillance, Epidemiology, and End Results (SEER) Program is a continuing project of the National Cancer Institute of the National Institutes of Health. Among its goals, in addition to assembling and reporting cancer statistics, are the monitoring of annual cancer incident trends and the promoting of studies designed to identify factors amenable to cancer control interventions. (From National Cancer Institute, NIH Publication No. 91-3074, October 1990)